These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 19011762)

  • 21.
    Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
    Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
    Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O
    Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
    Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
    Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
    Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
    Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
    Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
    Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
    Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL
    J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF; Schubert AD; Vassella E; Mariani L
    J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
    J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
    Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
    Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
    CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of
    Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
    [No Abstract]   [Full Text] [Related]  

  • 39. Glioblastoma Recurrence and the Role of O
    Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
    JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
    Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.